Ginkgo Bioworks (DNA) Competitors $10.61 +0.34 (+3.31%) Closing price 09/16/2025 03:59 PM EasternExtended Trading$10.49 -0.12 (-1.13%) As of 06:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DNA vs. TWST, GMTX, CGON, ALVO, CPRX, CNTA, TARS, MLYS, IBRX, and DNLIShould you be buying Ginkgo Bioworks stock or one of its competitors? The main competitors of Ginkgo Bioworks include Twist Bioscience (TWST), Gemini Therapeutics (GMTX), CG Oncology (CGON), Alvotech (ALVO), Catalyst Pharmaceuticals (CPRX), Centessa Pharmaceuticals (CNTA), Tarsus Pharmaceuticals (TARS), Mineralys Therapeutics (MLYS), ImmunityBio (IBRX), and Denali Therapeutics (DNLI). These companies are all part of the "pharmaceutical products" industry. Ginkgo Bioworks vs. Its Competitors Twist Bioscience Gemini Therapeutics CG Oncology Alvotech Catalyst Pharmaceuticals Centessa Pharmaceuticals Tarsus Pharmaceuticals Mineralys Therapeutics ImmunityBio Denali Therapeutics Ginkgo Bioworks (NYSE:DNA) and Twist Bioscience (NASDAQ:TWST) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk. Do insiders & institutionals believe in DNA or TWST? 78.6% of Ginkgo Bioworks shares are held by institutional investors. 9.7% of Ginkgo Bioworks shares are held by insiders. Comparatively, 3.0% of Twist Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has stronger earnings & valuation, DNA or TWST? Twist Bioscience has higher revenue and earnings than Ginkgo Bioworks. Twist Bioscience is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGinkgo Bioworks$227.04M2.77-$547.03M-$5.86-1.81Twist Bioscience$312.97M5.22-$208.73M-$1.45-18.68 Is DNA or TWST more profitable? Twist Bioscience has a net margin of -23.51% compared to Ginkgo Bioworks' net margin of -136.56%. Twist Bioscience's return on equity of -29.03% beat Ginkgo Bioworks' return on equity.Company Net Margins Return on Equity Return on Assets Ginkgo Bioworks-136.56% -43.25% -22.29% Twist Bioscience -23.51%-29.03%-21.77% Does the media refer more to DNA or TWST? In the previous week, Twist Bioscience had 20 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 21 mentions for Twist Bioscience and 1 mentions for Ginkgo Bioworks. Ginkgo Bioworks' average media sentiment score of 1.42 beat Twist Bioscience's score of 0.64 indicating that Ginkgo Bioworks is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ginkgo Bioworks 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Twist Bioscience 10 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend DNA or TWST? Ginkgo Bioworks currently has a consensus target price of $9.50, indicating a potential downside of 10.46%. Twist Bioscience has a consensus target price of $49.40, indicating a potential upside of 82.42%. Given Twist Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Twist Bioscience is more favorable than Ginkgo Bioworks.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ginkgo Bioworks 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Twist Bioscience 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.73 Which has more risk & volatility, DNA or TWST? Ginkgo Bioworks has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500. Comparatively, Twist Bioscience has a beta of 2.31, suggesting that its stock price is 131% more volatile than the S&P 500. SummaryTwist Bioscience beats Ginkgo Bioworks on 12 of the 16 factors compared between the two stocks. Get Ginkgo Bioworks News Delivered to You Automatically Sign up to receive the latest news and ratings for DNA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNA vs. The Competition Export to ExcelMetricGinkgo BioworksMED IndustryMedical SectorNYSE ExchangeMarket Cap$607.98M$3.12B$5.73B$21.51BDividend YieldN/A2.36%5.90%3.50%P/E Ratio-1.8121.1676.3829.83Price / Sales2.77446.35521.3753.44Price / CashN/A45.4037.1724.76Price / Book0.819.6213.664.53Net Income-$547.03M-$53.28M$3.28B$998.53M7 Day Performance3.54%1.01%0.88%1.09%1 Month Performance-19.38%4.58%4.67%4.39%1 Year Performance56.03%8.35%80.92%13.83% Ginkgo Bioworks Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNAGinkgo Bioworks1.6524 of 5 stars$10.61+3.3%$9.50-10.5%+70.4%$607.98M$227.04M-1.81640Positive NewsTWSTTwist Bioscience3.9492 of 5 stars$26.25+1.9%$49.40+88.2%-41.8%$1.58B$312.97M-18.10990GMTXGemini TherapeuticsN/A$60.76+0.9%N/A+25.3%$2.63BN/A-60.7630CGONCG Oncology2.4484 of 5 stars$33.69+1.9%$53.91+60.0%-3.4%$2.57B$1.14M-19.0361News CoverageAnalyst ForecastInsider TradeALVOAlvotech3.7274 of 5 stars$8.16-2.0%$14.00+71.6%-26.8%$2.46B$560.10M35.481,032Positive NewsShort Interest ↓CPRXCatalyst Pharmaceuticals4.9544 of 5 stars$20.08-1.0%$33.20+65.3%-1.8%$2.46B$491.73M12.1780Positive NewsCNTACentessa Pharmaceuticals3.1287 of 5 stars$18.03+14.6%$31.45+74.5%+29.6%$2.41B$15M-10.07200Insider TradeHigh Trading VolumeTARSTarsus Pharmaceuticals2.5046 of 5 stars$56.89-1.3%$66.67+17.2%+58.7%$2.40B$182.95M-24.4250Positive NewsMLYSMineralys Therapeutics2.9191 of 5 stars$35.93+3.2%$36.60+1.9%+222.6%$2.38BN/A-10.0928Insider TradeIBRXImmunityBio2.5161 of 5 stars$2.41+0.4%$10.75+346.1%-19.5%$2.28B$56.60M-5.02590DNLIDenali Therapeutics4.2948 of 5 stars$15.50+0.5%$33.62+116.9%-56.3%$2.27B$330.53M-5.54430Positive News Related Companies and Tools Related Companies Twist Bioscience Competitors Gemini Therapeutics Competitors CG Oncology Competitors Alvotech Competitors Catalyst Pharmaceuticals Competitors Centessa Pharmaceuticals Competitors Tarsus Pharmaceuticals Competitors Mineralys Therapeutics Competitors ImmunityBio Competitors Denali Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:DNA) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ginkgo Bioworks Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ginkgo Bioworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
